![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ATI Physical Therapy Inc | NYSE:ATIP | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.88 | 0 | 12:00:00 |
Drove Continued Growth in Visits, Rate per Visit, Revenue and Adjusted EBITDA
Advanced Company's Capacity to Expand Patient Access to High-Quality Care
BOLINGBROOK, Ill., Aug. 5, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today reported financial results for the second quarter ended June 30, 2024.
"We again experienced notable growth in the second quarter, with over 1,500 more patient visits each day compared to the same period last year," said Sharon Vitti, Chief Executive Officer of ATI. "Demand for our services remains strong, and our growing clinical base continues to execute on providing access and quality outcomes for our patients. Because of their hard work, we saw year-over-year growth in the business."
Ms. Vitti added, "We also saw higher rates per visit compared to the prior year due to the dedication of our payor and revenue cycle management teams. Equally exciting, we were recently notified by CMS that we have received an exceptional MIPS rating for the 5th consecutive year, a distinction recognizing the high-quality care we deliver every day. The ATI family is proud of this honor."
Joe Jordan, Chief Financial Officer of ATI, commented, "Our financial progress is a direct result of our strategic focus on people and operations. For the third quarter, we are guiding revenue to be between $180 million and $190 million and Adjusted EBITDA1 to be between $9 to $14 million."
Second Quarter 2024 Results
Supplemental tables of key performance metrics for the first quarter of 2022 through the second quarter of 2024 are presented after the financial statements at the end of this press release. Commentary on performance results in the second quarter of 2024 is as follows:
Additionally, ATI closed 2 clinics and divested 4 clinics during the quarter in connection with the Company's ongoing footprint optimization initiative, resulting in 878 clinics at the end of the quarter.
Q3-2024 Guidance
For the third quarter of 2024, ATI expects net revenue to be in the range of $180 million to $190 million, which represents approximately 1% to 7% year-over-year growth. The Company anticipates it will continue growing patient visits through 2024 as it executes on its commercial, people, and operations strategies. ATI expects Adjusted EBITDA4 in the third quarter of 2024 to be in the range of $9 million to $14 million.
1 Refer to "Non-GAAP Financial Measures" below. |
2 Ibid. |
3 Ibid. |
4 Ibid. |
Second Quarter 2024 Earnings Conference Call
Management will host a conference call at 5 p.m. Eastern Time on August 5, 2024, to review second quarter 2024 financial results. The conference call can be accessed via a live audio webcast. To join, please access the following web link, ATI Physical Therapy, Inc. Q2 2024 Earnings Conference Call, on the Company's Investor Relations website at https://investors.atipt.com at least 15 minutes early to register, and download and install any necessary audio software. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About ATI Physical Therapy
At ATI Physical Therapy, we are committed to making every life an active life. We provide convenient access to high-quality care to prevent and treat musculoskeletal (MSK) pain. Our approximately 900 locations in 24 states and virtual practice operate under the largest single-branded platform built to support standardized clinical guidelines and operating processes. With outcomes from more than 3 million unique patient cases, ATI strives to utilize quality standards designed to deliver proven, predictable, and impactful patient outcomes. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT™, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.
Forward-Looking Statements
All statements other than statements of historical facts contained in this communication are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the impact of physical therapist attrition and ability to achieve and maintain clinical staffing levels and clinician productivity, anticipated visit and referral volumes and other factors on the Company's overall profitability, and estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.
These forward-looking statements are subject to a number of risks and uncertainties, including:
If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
Investors should also review those factors discussed in the Company' Form 10-K and Form 10-Q for the fiscal year ended December 31, 2023, and quarter ended June 30, 2024, respectively, under the heading "Risk Factors," and other documents filed, or to be filed, by ATI with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on the business of the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements after the date they are made or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, except as required by law.
In addition, statements of belief and similar statements reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to the Company, as applicable, as of the date of this communication, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
Non-GAAP Financial Measures
To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "Adjusted EBITDA" and "Adjusted EBITDA margin." ATI believes Adjusted EBITDA and Adjusted EBITDA margin (i.e., Adjusted EBITDA divided by Net Revenue) assist investors and analysts in comparing the Company's operating performance across reporting periods on a consistent basis by excluding items that it does not believe are indicative of ATI's core operating performance.
Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which ATI operates and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of the Company's business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare ATI's performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.
Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or the ratio of net income (loss) to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of cash available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of the Company's results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
Please see "Reconciliation of GAAP to Non-GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures. We are unable to provide a reconciliation between forward-looking Adjusted EBITDA to its comparable GAAP financial measure without unreasonable effort, due to the high difficulty and impracticability of predicting certain amounts required by GAAP with a reasonable degree of accuracy by the date of this release.
Contacts:
Investor Relations
Joanne Fong
SVP, Treasurer and Head of Investor Relations
ATI Physical Therapy
investors@atipt.com
331-273-4891
Media Inquiries
Genesa Garbarino
Garbo Communications
genesa@garbo.agency
424-499-7025
ATI Physical Therapy Condensed Consolidated Statements of Operations ($ in thousands) (unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
June 30, | June 30, | June 30, | June 30, | ||||
Net patient revenue | $ 172,755 | $ 156,938 | $ 338,162 | $ 307,692 | |||
Other revenue | 15,357 | 15,399 | 31,422 | 31,577 | |||
Net revenue | 188,112 | 172,337 | 369,584 | 339,269 | |||
Cost of services: | |||||||
Salaries and related costs | 102,541 | 95,327 | 201,869 | 186,030 | |||
Rent, clinic supplies, contract labor and other | 53,168 | 50,437 | 108,429 | 103,315 | |||
Provision for doubtful accounts | 2,435 | 2,360 | 7,416 | 6,485 | |||
Total cost of services | 158,144 | 148,124 | 317,714 | 295,830 | |||
Selling, general and administrative expenses | 23,082 | 36,573 | 49,284 | 67,168 | |||
Long-lived asset impairment charges | 260 | — | 738 | — | |||
Operating income (loss) | 6,626 | (12,360) | 1,848 | (23,729) | |||
Change in fair value of 2L Notes | (5,618) | (7,010) | (11,025) | (7,010) | |||
Change in fair value of warrant liability and contingent common shares liability | (148) | (990) | (251) | (1,501) | |||
Interest expense, net | 14,896 | 16,682 | 29,379 | 30,618 | |||
Other expense (income), net | 61 | 618 | (33) | 972 | |||
Loss before taxes | (2,565) | (21,660) | (16,222) | (46,808) | |||
Income tax (benefit) expense | (13) | 89 | (147) | 151 | |||
Net loss | (2,552) | (21,749) | (16,075) | (46,959) | |||
Net income attributable to non-controlling interests | 1,183 | 956 | 2,311 | 2,016 | |||
Net loss attributable to ATI Physical Therapy, Inc. | (3,735) | (22,705) | (18,386) | (48,975) | |||
Less: Series A Senior Preferred Stock redemption value adjustments | 387 | 44,696 | (1,175) | 44,696 | |||
Less: Series A Senior Preferred Stock cumulative dividend | 6,439 | 5,709 | 12,622 | 11,012 | |||
Net loss available to common stockholders | $ (10,561) | $ (73,110) | $ (29,833) | $ (104,683) | |||
Loss per share of Class A common stock: | |||||||
Basic | $ (2.43) | $ (17.74) | $ (7.00) | $ (25.47) | |||
Diluted | $ (2.43) | $ (17.74) | $ (7.00) | $ (25.47) | |||
Weighted average shares outstanding: | |||||||
Basic and diluted | 4,346 | 4,122 | 4,263 | 4,110 |
ATI Physical Therapy Condensed Consolidated Balance Sheets ($ in thousands) (unaudited) | |||
June 30, 2024 | December 31, 2023 | ||
Assets: | |||
Current assets: | |||
Cash and cash equivalents | $ 32,963 | $ 36,802 | |
Accounts receivable (net of allowance for doubtful accounts of $48,823 and | 100,043 | 88,512 | |
Prepaid expenses | 13,039 | 12,920 | |
Insurance recovery receivable | 29,048 | 23,981 | |
Other current assets | 1,054 | 4,367 | |
Assets held for sale | 731 | 2,056 | |
Total current assets | 176,878 | 168,638 | |
Property and equipment, net | 88,574 | 100,422 | |
Operating lease right-of-use assets | 184,756 | 194,423 | |
Goodwill, net | 289,650 | 289,650 | |
Trade name and other intangible assets, net | 245,615 | 245,858 | |
Other non-current assets | 5,063 | 4,290 | |
Total assets | $ 990,536 | $ 1,003,281 | |
Liabilities, Mezzanine Equity and Stockholders' Equity: | |||
Current liabilities: | |||
Accounts payable | $ 10,933 | $ 14,704 | |
Accrued expenses and other liabilities | 89,040 | 88,435 | |
Current portion of operating lease liabilities | 50,520 | 51,530 | |
Liabilities held for sale | 714 | 1,778 | |
Total current liabilities | 151,207 | 156,447 | |
Long-term debt, net (1) | 441,177 | 433,578 | |
2L Notes due to related parties, at fair value | 89,997 | 79,472 | |
Deferred income tax liabilities | 21,220 | 21,367 | |
Operating lease liabilities | 174,623 | 185,602 | |
Other non-current liabilities | 1,927 | 2,277 | |
Total liabilities | 880,151 | 878,743 | |
Commitments and contingencies | |||
Mezzanine equity: | |||
Series A Senior Preferred Stock, $0.0001 par value; 1.0 million shares authorized; | 231,840 | 220,393 |
(1) | Includes $17.0 million of principal amount of debt due to related parties as of June 30, 2024 and December 31, 2023, respectively. |
Stockholders' equity: | |||
Class A common stock, $0.0001 par value; 470.0 million shares authorized; 4.5 million | — | — | |
Treasury stock, at cost, 0.089 million shares and 0.007 million shares at June 30, 2024 | (713) | (219) | |
Additional paid-in capital | 1,300,910 | 1,308,119 | |
Accumulated other comprehensive income | 148 | 406 | |
Accumulated deficit | (1,427,692) | (1,409,306) | |
Total ATI Physical Therapy, Inc. equity | (127,347) | (101,000) | |
Non-controlling interests | 5,892 | 5,145 | |
Total stockholders' equity | (121,455) | (95,855) | |
Total liabilities, mezzanine equity and stockholders' equity | $ 990,536 | $ 1,003,281 |
ATI Physical Therapy Condensed Consolidated Statements of Cash Flows ($ in thousands) (unaudited) | |||
Six Months Ended | |||
June 30, 2024 | June 30, 2023 | ||
Operating activities: | |||
Net loss | $ (16,075) | $ (46,959) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Long-lived asset impairment charges | 738 | — | |
Depreciation and amortization | 17,312 | 19,041 | |
Provision for doubtful accounts | 7,416 | 6,485 | |
Deferred income tax provision | (147) | 151 | |
Non-cash lease expense related to right-of-use assets | 23,740 | 23,836 | |
Non-cash share-based compensation | 4,238 | 4,208 | |
Amortization of debt issuance costs and original issue discount | 1,443 | 1,554 | |
Non-cash interest expense | — | 4,318 | |
Loss on extinguishment of debt | — | 444 | |
Gain (Loss) on disposal and sale of assets | (181) | 793 | |
Change in fair value of 2L Notes | (11,025) | (7,010) | |
Change in fair value of warrant liability and contingent common shares liability | (251) | (1,501) | |
Change in fair value of non-designated derivative instrument | (494) | — | |
Changes in: | |||
Accounts receivable, net | (18,947) | (6,105) | |
Insurance recovery receivable | (5,067) | — | |
Prepaid expenses and other current assets | (168) | 1,834 | |
Other non-current assets | (773) | 89 | |
Accounts payable | (3,664) | 119 | |
Accrued expenses and other liabilities | 620 | 15,158 | |
Operating lease liabilities | (26,530) | (21,830) | |
Other non-current liabilities | (37) | 56 | |
Net cash used in operating activities | (27,852) | (5,319) | |
Investing activities: | |||
Purchases of property and equipment | (5,692) | (9,990) | |
Proceeds from sale of property and equipment | 106 | — | |
Proceeds from sale of clinics | 434 | 355 | |
Payment of holdback liabilities related to acquisitions | — | (490) | |
Net cash used in investing activities | (5,152) | (10,125) | |
Financing activities: | |||
Proceeds from 2L Notes from related parties | 25,000 | 3,243 | |
Financing transaction costs | — | (6,287) | |
Deferred financing costs | — | (84) | |
Proceeds from revolving line of credit | 31,153 | — | |
Payments on revolving line of credit | (24,923) | (24,750) | |
Payment of contingent consideration liabilities | (7) | (397) | |
Taxes paid on behalf of employees for shares withheld | (494) | (66) | |
Distribution to non-controlling interest holders | (1,564) | (1,675) | |
Net cash provided by (used in) financing activities | 29,165 | (30,016) | |
Changes in cash and cash equivalents: | |||
Net decrease in cash and cash equivalents | (3,839) | (45,460) | |
Cash and cash equivalents at beginning of period | 36,802 | 83,139 | |
Cash and cash equivalents at end of period | $ 32,963 | $ 37,679 | |
Supplemental noncash disclosures: | |||
Derivative changes in fair value (1) | $ 258 | $ 4,306 | |
Purchases of property and equipment in accounts payable | $ 2,538 | $ 1,495 | |
Exchange of Senior Secured Term Loan for related party 2L Notes | $ — | $ 100,000 | |
Debt discount on Senior Secured Term Loan | $ — | $ (1,797) | |
Capital contribution from recognition of delayed draw right asset | $ — | $ 690 | |
Series A Senior Preferred Stock dividends and redemption value adjustments | $ 11,447 | $ 73,584 | |
Exchange of delayed draw right for related party 2L Notes | $ 3,450 | $ — | |
Other supplemental disclosures: | |||
Cash paid for interest | $ 28,556 | $ 24,698 | |
Cash received from hedging activities | $ 266 | $ 5,135 | |
Cash paid for taxes, net of refunds | $ 20 | $ 3 |
(1) | Derivative changes in fair value related to unrealized loss on cash flow hedges, including the impact of reclassifications. |
ATI Physical Therapy, Inc. Supplemental Tables of Key Performance Metrics | |||||
Financial Metrics ($ in 000's) | |||||
Net Patient | Other Revenue | Net Revenue | Adjusted | Adj EBITDA | |
Q1 2022 | $138,925 | $14,897 | $153,822 | $(4,695) | (3.1) % |
Q2 2022 | $148,506 | $14,787 | $163,293 | $5,436 | 3.3 % |
Q3 2022 | $142,313 | $14,479 | $156,792 | $(392) | (0.3) % |
Q4 2022 | $146,196 | $15,568 | $161,764 | $6,363 | 3.9 % |
Q1 2023 | $150,754 | $16,178 | $166,932 | $4,790 | 2.9 % |
Q2 2023 | $156,938 | $15,399 | $172,337 | $9,338 | 5.4 % |
Q3 2023 | $162,258 | $15,197 | $177,455 | $9,429 | 5.3 % |
Q4 2023 | $166,145 | $16,147 | $182,292 | $12,675 | 7.0 % |
Q1 2024 | $165,407 | $16,065 | $181,472 | $6,463 | 3.6 % |
Q2 2024 | $172,755 | $15,357 | $188,112 | $16,579 | 8.8 % |
Operational Metrics | |||||||
Visits per Day (1) | Clinical FTE (2) | VPD per cFTE (3) | ATI Clinician Headcount (4) | Contractor | ATI Clinician Headcount | ||
Adds (6) | Turnover (7) | ||||||
Q1 2022 | 21,062 | 2,466 | 8.5 | 2,658 | 158 | 25 % | 23 % |
Q2 2022 | 22,403 | 2,465 | 9.1 | 2,647 | 151 | 26 % | 28 % |
Q3 2022 | 21,493 | 2,465 | 8.7 | 2,691 | 151 | 33 % | 25 % |
Q4 2022 | 22,316 | 2,476 | 9.0 | 2,662 | 123 | 19 % | 26 % |
Q1 2023 | 22,701 | 2,423 | 9.4 | 2,629 | 168 | 21 % | 27 % |
Q2 2023 | 23,412 | 2,452 | 9.5 | 2,681 | 185 | 27 % | 19 % |
Q3 2023 | 23,435 | 2,524 | 9.3 | 2,786 | 214 | 35 % | 20 % |
Q4 2023 | 24,238 | 2,584 | 9.4 | 2,759 | 179 | 15 % | 21 % |
Q1 2024 | 23,837 | 2,560 | 9.3 | 2,787 | 206 | 18 % | 16 % |
Q2 2024 | 24,921 | 2,589 | 9.6 | 2,797 | 215 | 20 % | 21 % |
(1) | Equals patient visits divided by operating days. |
(2) | Represents clinical staff hours divided by 8 hours divided by number of paid days. |
(3) | Equals patient visits divided by operating days divided by clinical full-time equivalent employees. |
(4) | Represents ATI employee clinician headcount at end of period. |
(5) | Represents contractor clinician headcount at end of period. |
(6) | Represents ATI employee clinician headcount new hire adds divided by average headcount, multiplied by 4 to annualize. |
(7) | Represents ATI employee clinician headcount separations divided by average headcount, multiplied by 4 to annualize. |
Unit Economics: PT Clinics ($ actual) | |||||||
Ending Clinic Count | PT per Clinic (1) | VPD per Clinic (2) | PT Rate per Visit (3) | PT Salaries per Visit (4) | PT Rent and Other per Clinic (5) | PT Provision as % PT | |
Q1 2022 | 922 | $151,225 | 22.9 | $103.06 | $55.47 | $54,472 | 3.7 % |
Q2 2022 | 926 | $160,431 | 24.2 | $103.57 | $53.64 | $53,017 | 2.4 % |
Q3 2022 | 929 | $153,410 | 23.2 | $103.46 | $56.20 | $53,945 | 2.0 % |
Q4 2022 | 923 | $157,993 | 24.1 | $103.99 | $54.92 | $51,252 | 1.7 % |
Q1 2023 | 909 | $165,846 | 25.0 | $103.76 | $52.98 | $56,338 | 2.7 % |
Q2 2023 | 911 | $172,207 | 25.7 | $104.74 | $54.81 | $53,866 | 1.5 % |
Q3 2023 | 900 | $179,224 | 25.9 | $109.90 | $57.47 | $57,012 | 2.1 % |
Q4 2023 | 896 | $184,948 | 27.0 | $108.81 | $56.56 | $57,109 | 0.9 % |
Q1 2024 | 884 | $186,409 | 26.9 | $108.42 | $56.68 | $60,800 | 3.0 % |
Q2 2024 | 878 | $196,610 | 28.4 | $108.32 | $56.22 | $59,232 | 1.4 % |
(1) | Equals Net Patient Revenue divided by average clinics over the quarter. |
(2) | Equals patient visits divided by operating days divided by average clinics over the quarter. |
(3) | Equals Net Patient Revenue divided by patient visits. |
(4) | Equals estimated patient-related portion of Salaries and Related Costs divided by patient visits. |
(5) | Equals estimated patient-related portion of Rent, Clinic Supplies, Contract Labor and Other divided by average clinics over the quarter. |
(6) | Equals estimated patient-related portion of Provision for Doubtful Accounts divided by Net Patient Revenue. |
Customer Satisfaction Metrics | |||||||
Net Promoter | Google Star | ||||||
Q1 2022 | 74 | 4.9 | |||||
Q2 2022 | 75 | 4.9 | |||||
Q3 2022 | 76 | 4.8 | |||||
Q4 2022 | 76 | 4.9 | |||||
Q1 2023 | 76 | 4.8 | |||||
Q2 2023 | 74 | 4.8 | |||||
Q3 2023 | 75 | 4.9 | |||||
Q4 2023 | 76 | 4.9 | |||||
Q1 2024 | 74 | 4.8 | |||||
Q2 2024 | 75 | 4.9 |
(1) | NPS measures customer experience from ATI patient survey responses. The score is calculated as the percentage of promoters less the percentage of detractors. |
(2) | A Google Star rating is a five-star rating scale that ranks businesses based on customer reviews. Customers are given the opportunity to leave a business review after interacting with a business, which involves choosing from one star (poor) to five stars (excellent). |
ATI Physical Therapy, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures ($ in thousands) (unaudited) | ||
Three Months Ended | ||
June 30, | March 31, | |
2024 | 2024 | |
Net loss | $ (2,552) | $ (13,523) |
Plus (minus): | ||
Net income attributable to non-controlling interests | (1,183) | (1,128) |
Interest expense, net | 14,896 | 14,483 |
Income tax benefit | (13) | (134) |
Depreciation and amortization expense | 8,294 | 8,732 |
EBITDA | $ 19,442 | $ 8,430 |
Long-lived asset impairment charges (1) | 260 | 478 |
Change in fair value of 2L Notes (2) | (5,618) | (5,407) |
Changes in fair value of warrant liability and contingent common shares liability (3) | (148) | (103) |
Share-based compensation (4) | 1,972 | 2,330 |
Non-ordinary legal and regulatory matters (5) | 1,853 | 1,178 |
Legal cost insurance reimbursements (6) | (1,039) | (256) |
Change in fair value of non-designated derivative instrument (7) | (143) | (351) |
Transaction costs (8) | — | 164 |
Adjusted EBITDA | $ 16,579 | $ 6,463 |
Adjusted EBITDA margin | 8.8 % | 3.6 % |
(1) | Represents non-cash charges related to the write-down of long-lived assets. |
(2) | Represents non-cash amounts related to the change in the estimated fair value of the 2L Notes. |
(3) | Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares. |
(4) | Represents charges related to share-based compensation awards, which vary from period to period based on the timing of awards and vesting conditions. |
(5) | Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter. |
(6) | Represents insurance reimbursements for legal costs incurred related to the previously disclosed ATIP stockholder class action complaints and derivative complaint. |
(7) | Represents non-cash amounts related to the change in estimated fair value of derivative not designated in a hedging relationship. |
(8) | Represents non-capitalizable debt and capital transaction costs. |
ATI Physical Therapy, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures ($ in thousands) (unaudited) | ||||
Three Months Ended | ||||
December 31, | September 30, | June 30, | March 31, | |
2023 | 2023 | 2023 | 2023 | |
Net loss | $ (4,508) | $ (14,611) | $ (21,749) | $ (25,210) |
Plus (minus): | ||||
Net income attributable to non-controlling interests | (1,115) | (586) | (956) | (1,060) |
Interest expense, net | 14,943 | 15,478 | 16,682 | 13,936 |
Income tax expense | 2,286 | 131 | 89 | 62 |
Depreciation and amortization expense | 8,915 | 9,154 | 9,211 | 9,564 |
EBITDA | $ 20,521 | $ 9,566 | $ 3,277 | $ (2,708) |
Goodwill, intangible and other asset impairment charges (1) | 5,591 | — | — | — |
Change in fair value of 2L Notes (2) | (15,976) | (1,485) | (7,010) | — |
Changes in fair value of warrant liability and contingent common shares liability (3) | (457) | (394) | (990) | (511) |
Legal cost insurance reimbursements (4) | (3,597) | (4,274) | — | — |
Non-ordinary legal and regulatory matters (5) | 3,646 | 3,559 | 2,001 | 1,523 |
Share-based compensation | 2,274 | 2,286 | 2,755 | 1,478 |
Transaction costs (6) | 131 | 215 | 8,714 | 5,408 |
Change in fair value of non-designated derivative instrument | 542 | (67) | — | — |
Pre-opening de novo costs (7) | — | 23 | 147 | 172 |
Loss on debt extinguishment (8) | — | — | 444 | — |
Non-recurring labor related credits (9) | — | — | — | (702) |
Reorganization and severance costs (10) | — | — | — | 130 |
Adjusted EBITDA | $ 12,675 | $ 9,429 | $ 9,338 | $ 4,790 |
Adjusted EBITDA margin | 7.0 % | 5.3 % | 5.4 % | 2.9 % |
(1) | Represents non-cash charges related to the write-down of long-lived assets. |
(2) | Represents non-cash amounts related to the change in the estimated fair value of the 2L Notes. |
(3) | Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares. |
(4) | Represents insurance reimbursements for legal costs incurred related to the previously disclosed ATIP stockholder class action complaints and derivative complaint. |
(5) | Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter. |
(6) | Represents non-capitalizable debt and capital transaction costs. |
(7) | Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening. |
(8) | Represents charges related to the loss on debt extinguishment recognized as part of the 2023 Debt Restructuring. |
(9) | Represents realized benefit of labor related credit, that was not previously considered probable and relates to prior years. |
(10) | Represents severance costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions. |
ATI Physical Therapy, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures ($ in thousands) (unaudited) | ||||
Three Months Ended | ||||
December 31, | September 30, | June 30, | March 31, | |
2022 | 2022 | 2022 | 2022 | |
Net loss | $ (102,407) | $ (116,694) | $ (135,723) | $ (138,223) |
Plus (minus): | ||||
Net (income) loss attributable to non-controlling interests | (358) | 376 | 177 | 473 |
Interest expense, net | 13,463 | 11,780 | 11,379 | 8,656 |
Income tax benefit | (4,998) | (7,218) | (13,033) | (23,281) |
Depreciation and amortization expense | 9,979 | 9,907 | 10,055 | 9,900 |
EBITDA | $ (84,321) | $ (101,849) | $ (127,145) | $ (142,475) |
Goodwill, intangible and other asset impairment charges (1) | 96,038 | 106,663 | 127,820 | 155,741 |
Goodwill, intangible and other asset impairment charges attributable to non-controlling interests (1) | (364) | (457) | (654) | (940) |
Changes in fair value of warrant liability and contingent common shares liability (2) | (10,357) | (7,720) | (2,680) | (26,011) |
Loss on debt extinguishment (3) | — | — | — | 2,809 |
Loss on legal settlement (4) | — | — | 3,000 | — |
Share-based compensation | 1,544 | 1,920 | 2,004 | 1,964 |
Non-ordinary legal and regulatory matters (5) | 937 | 772 | 2,202 | 2,497 |
Pre-opening de novo costs (6) | 101 | 224 | 286 | 381 |
Transaction costs (7) | 1,093 | 55 | 603 | 1,538 |
Reorganization and severance costs (8) | 1,797 | — | — | — |
Non-recurring labor related credits (9) | (105) | — | — | — |
Gain on sale of Home Health service line, net | — | — | — | (199) |
Adjusted EBITDA | $ 6,363 | $ (392) | $ 5,436 | $ (4,695) |
Adjusted EBITDA margin | 3.9 % | (0.3) % | 3.3 % | (3.1) % |
(1) | Represents non-cash charges related to the write-down of goodwill, trade name indefinite-lived intangible and other assets. |
(2) | Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares. |
(3) | Represents charges related to the derecognition of the unamortized deferred financing costs and original issuance discount associated with the full repayment of the 2016 first lien term loan. |
(4) | Represents charge for net settlement liability related to billing dispute. |
(5) | Represents non-ordinary course legal costs related to the previously disclosed ATIP stockholder class action complaints, derivative complaint, and SEC matter. |
(6) | Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening. |
(7) | Represents costs related to the Business Combination with FVAC II and non-capitalizable debt and capital transaction costs. |
(8) | Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions. |
(9) | Represents realized benefit of labor related credit, that was not previously considered probable and relates to prior years. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/ati-physical-therapy-reports-second-quarter-2024-results-302213867.html
SOURCE ATI Physical Therapy
Copyright 2024 PR Newswire
1 Year ATI Physical Therapy Chart |
1 Month ATI Physical Therapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions